Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.59
$0.0654.28%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.62M | 6.49M | 3.24M | -2.20M | -4.60M |
| Total Depreciation and Amortization | 346.00K | 334.00K | 329.00K | 319.00K | 322.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.00K | 610.00K | 2.21M | 426.00K | 377.00K |
| Change in Net Operating Assets | -1.84M | -3.45M | -1.67M | -2.15M | 8.08M |
| Cash from Operations | -5.06M | 3.99M | 4.11M | -3.61M | 4.19M |
| Capital Expenditure | -306.00K | -425.00K | -87.00K | -172.00K | -598.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 3.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.00K | -14.90M | 20.41M | -8.00K | -8.00K |
| Cash from Investing | -312.00K | -15.32M | 20.33M | -180.00K | -606.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -20.42M | -- | -- |
| Issuance of Common Stock | 5.08M | 3.63M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.08M | 3.63M | -20.42M | -- | -- |
| Foreign Exchange rate Adjustments | -8.00K | 54.00K | -2.00K | -20.00K | -7.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -302.00K | -7.65M | 4.01M | -3.81M | 3.58M |